Status:
COMPLETED
Parasite Clearance and Protection from Infection (PCPI) in Cameroon
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Conditions:
Malaria
Eligibility:
All Genders
3-5 years
Phase:
PHASE3
Brief Summary
The Cameroon PCPI study will measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP. The total number of part...
Detailed Description
The World Health Organization (WHO) recently published new malaria chemoprevention guidelines that included a recommendation for the provision of perennial malaria chemoprevention (PMC) with sulfadoxi...
Eligibility Criteria
Inclusion
- Be 3-5 years old
- Exhibit no symptoms of malaria
- Have parents/guardians willing to have their child participate in all follow-up visits and seek care from study staff
- Reside in the study catchment area
Exclusion
- Have evidence of acute illness as determined by clinical examination
- Exhibit symptoms of malaria (axillary fever ≥ 37.5 °C and / or history of fever in past 48 hours)
- Have known allergy to study medications
- Have received antimalarial treatment or azithromycin within 28 days prior to screening
- Be concomitantly receiving co-trimoxazole (trimethoprim-sulfamethoxazole)
- Be categorised as severely malnourished according to WHO child growth standards
Key Trial Info
Start Date :
June 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 5 2025
Estimated Enrollment :
902 Patients enrolled
Trial Details
Trial ID
NCT06173206
Start Date
June 10 2024
End Date
March 5 2025
Last Update
March 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Malantouen District Hospital Catchment Area
Magba, Cameroon